YichenWu

Associate

Beijing + 86.10.5866.1228

Connect:

Share

Yichen Wu focuses his practice on antitrust and competition law issues, including merger filing reviews, government investigations and enforcement, antitrust consultation and compliance, and private litigation. He serves companies in areas such as agriculture, manufacturing, life sciences, semiconductors, telecommunications, internet platforms and infrastructure, transportation, trading, energy, and natural resources.

Yichen assists clients in connection with antitrust issues that arise throughout the merger and acquisition process, from premerger counseling through in-depth investigations across various jurisdictions. In addition to representing clients in antitrust investigations before authorities in China, Yichen serves clients on merger filings in the United States, EU, Japan, and Korea and advises on global corporate compliance programs. His experience also includes a number of cutting-edge cases involving the intersection of antitrust and intellectual property law. Yichen also conducts internal compliance and government investigations for violations of the Foreign Corrupt Practices Act (FCPA) and has represented companies in obtaining clearance before the Committee on Foreign Investment in the United States (CFIUS) and on government regulation issues (export control and economic sanctions).

Prior to joining Jones Day in 2017, Yichen worked as an antitrust associate in the Washington, D.C. office of a leading international law firm for four years.

Experience

  • Valmet completes statutory merger with NelesJones Day served as global merger control and foreign direct investment counsel to Valmet Oyj (excluding Finland) in its statutory merger with Neles Corporation.
  • PTTGC acquires allnex from AdventJones Day advised PTT Global Chemical Public Company Limited in the €4 billion acquisition of allnex Holding GmbH from Advent International.
  • EDF acquires 50% of Orange ConcessionsJones Day acted as antitrust counsel to EDF Invest on the merger control/antitrust aspects of its acquisition (together with the Caisse des Dépôts et Consignations (CDC) and the Caisse Nationale de Prévoyance (CNP)) of 50% of the capital and voting rights of Orange Concessions which is active in the roll out of fiber in France in less densely populated areas.
  • PolyOne acquires Clariant color and additive masterbatch business for $1.5 billionJones Day advised PolyOne Corporation in the $1.5 billion purchase of Clariant’s global color and additive masterbatch business.
  • JERA acquires minority stake in Formosa 2 offshore wind power projectJones Day advised JERA in the acquisition of a minority stake in the Formosa 2 offshore wind power project, located near Miaoli County off the west coast of Taiwan.
  • EDF and Masdar to form energy services companyJones Day acted as antitrust counsel to EDF (Electricité de France) in the formation of a joint venture company with Masdar (a subsidiary of Mubadala Investment Company) dedicated to energy efficiency and distributed solar power generation projects.
  • JERA acquires minority stake in Formosa 1 offshore wind power projectJones Day advised JERA in the acquisition of a minority stake in the Formosa 1 offshore wind power project, located off the north-western coast of Taiwan.
  • LORD Corporation acquired by Parker Hannifin for $3.675 billionJones Day advised LORD Corporation in its $3.675 billion acquisition by Parker Hannifin Corporation.
  • USG acquired by Gebr. Knauf for $7 billionJones Day advised USG Corporation in the acquisition by Gebr. Knauf KG ("Knauf") of all of the outstanding shares of USG in a transaction valued at $7 billion.
  • Oclaro sold to Lumentum for $1.8 billion in cash and stockJones Day advised Oclaro, Inc. in its $1.8 billion acquisition by Lumentum Holdings Inc.
  • Greystar recapitalizes Chapter student accommodation portfolio in Central LondonJones Day advised Greystar Real Estate Partners, LLC in a recapitalization of its and PSP’s Chapter portfolio of student accommodation properties, one of the largest in Central London, by consolidating the portfolio under a new joint venture in which Allianz acquired an interest.
  • Glencore Singapore forms joint venture with Zhejiang Provincial PetroleumJones Day advised Glencore Singapore Pte. Ltd. on the formation of Zhejiang Petroleum Trading Co., Ltd., a joint venture with Zhejiang Provincial Petroleum Co., Ltd.
  • Safran completes €8.7 billion agreed tender offer targeting Zodiac Aerospace's shares creating global leader in aircraft equipmentJones Day represented Safran in connection with its €8.7 billion agreed tender offer targeting Zodiac Aerospace's shares to create a global leader in aircraft equipment.
  • PotashCorp combines with Agrium in $38 billion merger-of-equalsJones Day advised PotashCorp in its $38 billion all-stock merger-of-equals with Agrium.
  • Koch Disruptive Technologies leads $150 million investment in INSIGHTECJones Day advised Koch Disruptive Technologies, a subsidiary of Koch Industries, Inc. focused on finding and funding innovative and emerging companies, as the lead investor in a $150 million Series E funding round for INSIGHTEC, a commercial stage medical device company.
  • Ambry Genetics sold to joint venture formed by Konica Minolta and Innovation Network for up to $1.0 billionJones Day advised Ambry Genetics Corporation, a leading genetic testing corporation, in its sale to a newly formed joint venture between Konica Minolta, Inc. and Innovation Network Corporation of Japan for up to $1.0 billion (including earnouts).
  • Imerys merger with Kerneos receives antitrust clearanceJones Day represented Imerys S.A., a multinational manufacturer of industrial minerals, on the antitrust aspects of its €880 million acquisition of Kerneos, a global producer and supplier of specialty cements.
  • Sanofi and Lonza form joint venture to establish large-scale biologics production facility in SwitzerlandJones Day advised Sanofi in the formation of a joint venture with Lonza Group AG to build and operate a large-scale mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland.
    •

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.